Dechra Buys Gallant Pet to Enter Animal Regenerative Medicine
Dechra has acquired U.S. biotech Gallant Pet, adding off-the-shelf mesenchymal stromal cell therapies for pets, with a first product possibly arriving as early as 2027.
By Nathan Brooks
3 min read

What's News
- Dechra completed its acquisition of U.S. biotech Gallant Pet; financial terms were not disclosed
- First product from Gallant's pipeline could launch as early as 2027, pending regulatory outcomes
- Gallant develops ready-to-use mesenchymal stromal cell therapies prepared in advance, not per-animal
- The platform is designed to support multiple products across conditions and species
- Brand retention, employee transfers, and the first commercial indication were not disclosed
Dechra has completed its acquisition of Gallant Pet, a U.S. animal health biotechnology company developing ready-to-use mesenchymal stromal cell (MSC) therapies for companion animals. The deal moves Dechra beyond conventional veterinary pharmaceuticals and into regenerative medicine, a therapeutic modality it has not previously operated in.
Neither company disclosed the purchase price. Dechra expects the first product from Gallant's pipeline could become available as early as 2027, though development and regulatory outcomes remain uncertain.
Why off-the-shelf cell therapies matter
Mesenchymal stromal cells are being studied for their ability to interact with biological processes involved in inflammation, tissue repair, and immune response. Gallant's approach is to develop therapies prepared in advance rather than manufactured separately for each animal.
That ready-to-use model is the commercial hook. It could simplify storage, distribution, and administration compared with individually produced treatments — the kind of operational difference that determines whether a cell therapy is viable in general veterinary practice or confined to specialty clinics.
Gallant is targeting chronic and complex conditions in companion animals, including diseases where current treatment options focus primarily on symptom management. The platform is built to support a pipeline rather than a single product, creating room to investigate additional diseases and species — but only if the underlying technology demonstrates safety, effectiveness, manufacturing consistency, and regulatory compliance.
What does this change for practitioners?
For veterinarians, nothing is immediate. No product has approval, and the companies did not disclose the specific indication planned for the first commercial launch. What changes is the trajectory: a specialty animal health company with global reach now owns the manufacturing and clinical development risk of bringing MSC therapies through regulation.
Dechra plans to combine Gallant's cell-therapy research and manufacturing expertise with its own global veterinary relationships, specialty-care portfolio, and commercialization capabilities. The acquisition gives Gallant access to a larger organization capable of supporting clinical development, regulatory work, manufacturing scale, and distribution.
Dr. Cathy Knupp, Chief Scientific Officer of Dechra, framed the deal as a platform play:
"This acquisition is a strategic investment in expanding what's possible in veterinary care. By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant's scientific innovation and regenerative medicine platform, we're creating a strong foundation to bring new treatment options to veterinarians and their patients."
The open questions
Several details remain undisclosed. The companies did not say whether Gallant will retain its brand or which employees will transfer. Any new therapy will remain subject to successful development and to the regulatory requirements of each market where Dechra seeks approval — meaning the 2027 date is a best case, not a commitment.
Gallant CEO Dr. Linda Black emphasized alignment between the two companies:
"Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need. Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart. I'm incredibly proud of the team that got us here, and excited to keep pioneering together."
If Gallant's platform clears its first regulatory hurdles, Dechra will hold a manufacturing and distribution engine it can point at additional species and indications — the difference between a one-product bet and a repeatable therapeutic franchise.
Source: pulse2.com
More from Nathan Brooks
Show full bio
News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.
2,426 articles